about
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancerThe TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study.Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.EPCAM germ line deletions as causes of Lynch syndrome in Spanish patientsCirculating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancerMammographic density and breast cancer in women from high risk families.Clinical guideline seom: hereditary colorectal cancer.Cutaneous metastases of lung cancer.Diagnosis and current treatment of neurological paraneoplastic syndromes.A revision on cryoglobulinaemia associated to neoplastic diseases.Deposition-associated diseases related with a monoclonal compound.Capecitabine plus oxaliplatin for the treatment of colorectal cancer.Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.TTD consensus document on the diagnosis and management of hereditary colorectal cancer.Muscle metastasis of carcinoma.Tools for decision-making in older cancer patients. Role of the comprehensive geriatric assessment.Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.Oral chemotherapy in elderly women with metastatic breast cancer.First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.Current controversies in the management of metastatic colorectal cancer.Reduced risk of pancreatic cancer associated with asthma and nasal allergies.Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?Use of geriatric assessment and screening tools of frailty in elderly patients with prostate cancer. Review.Diagnosis and staging of pancreatic ductal adenocarcinoma.Desensitizing oxaliplatin-induced fever: a case report.A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk.Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.[Fever of unknown origin as first manifestation of two cases of cervix carcinoma]Refinement of screening for familial pancreatic cancer.PanGen-Fam: Spanish registry of hereditary pancreatic cancer.Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.P-016Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer.[Is positron emission tomography (PET) scan useful for studying the extent of gastrointestinal stromal tumors]Patient with resected anaplastic astrocytoma and an image suggestive of relapse.Intramedullary metastases due to non microcytic lung carcinoma.Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.Tracheo-esophageal fistula in a patient with esophageal cancer and stent.Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.Malignant uveitis masking a lymphocytic lymphoma.
P50
Q26821956-599CDBF4-1AE1-439A-A794-C9963A80A9C2Q33470715-877565C4-94E9-471D-8FB3-8C77A8AF1687Q33665450-606022CD-693C-476E-85EA-8C6D260852FDQ34239731-65CE9583-3A35-43D7-AB98-78A30B86AA7EQ35820329-3C401F01-7570-493E-8DF6-793DD223F593Q35842576-02B0DE75-A507-4B21-BA2A-A48A9939B779Q36400248-3CA3C99B-656F-48D8-825D-D10C6AE5AAA2Q36499586-1BD55D5A-19AD-4BFC-BFB6-5CBC8F406B8FQ36668497-81052D7C-1EAE-407C-AD70-F43E6DFDD9A9Q36803228-5EE0C7F1-43DA-4BD8-B893-5A74251FE61BQ37045073-9D8F6A1B-E7D8-45C8-BB8D-BC3845E03954Q37085987-1AE57CB8-5CD0-4FB2-873F-3C30342793B3Q37683316-87202F1F-6681-4F12-90E9-79A08F03188FQ37751548-D0A3E1B2-BA2C-4999-BE0A-932EE5D2B0F6Q37842969-D313BE36-FDD8-4C73-BCE6-B1211F10B1D4Q38084437-11C319B1-85C3-451F-A9FA-3FDF8F5FEE6FQ38084439-6976388D-9F47-40E0-83C0-83FABD125BD7Q38205044-35A78AD5-524B-402A-8E93-E3EC8C05BB72Q38411750-ED807CDE-A24A-4426-B2DF-26E479CDAB44Q38538213-6758E3AC-B80A-470C-BE17-1EA18223C7EAQ38656288-49CAE552-9498-48B1-9DDD-0D8636D7730FQ38796209-2836BD1C-3EBF-4F5B-B43F-CDB4FF617BE7Q39085255-D8D4EF3F-813B-4C0F-9E6F-E9945A8D155BQ39371341-8BE4C78B-89B8-4406-8B7A-B6A7C90BBDDFQ40220276-3EDEE949-0FA8-4F86-89DA-994293B26785Q40255128-0C4EA4A3-A7CC-4A92-8FBD-F257537517A8Q40325645-B5F52668-D6B9-49D9-9E50-B9DAB1B19D9CQ40466256-76EBB05E-2353-4DCD-A830-8CC3D2F0D234Q40736844-054F420D-19FF-4F80-9E06-743F7B883B09Q41545828-6B06D6EB-6561-4D8F-8553-938238CDDB4EQ42606229-5B504542-796B-4EC1-A464-EF37D9E3BF68Q46469084-F29DD9CE-2436-4C20-A427-A89D6F5EFC62Q46972893-BE016414-9BB9-4363-BB33-725433D6B1B3Q48337619-D7E1A719-F6AD-443D-8084-52291E8C9A46Q48491310-7714BA3E-A9A5-4CFC-A35D-17C962027C23Q51307312-71B89DE4-E58C-4F9A-85AD-E9BFF3CF113DQ51326404-4A2FE43E-30BD-4972-9C9B-37ACDCCAEAA7Q52868338-B96529CC-5E98-4377-B231-F948F8CE774FQ53280066-D3A570AE-A759-4B38-AA21-05944C07A4EFQ53510511-0B7124B6-1FD6-4A05-834F-C42F0B63D8D2
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
CARMEN GUILLEN PONCE
@ast
CARMEN GUILLEN PONCE
@en
CARMEN GUILLEN PONCE
@es
CARMEN GUILLEN PONCE
@nl
type
label
CARMEN GUILLEN PONCE
@ast
CARMEN GUILLEN PONCE
@en
CARMEN GUILLEN PONCE
@es
CARMEN GUILLEN PONCE
@nl
prefLabel
CARMEN GUILLEN PONCE
@ast
CARMEN GUILLEN PONCE
@en
CARMEN GUILLEN PONCE
@es
CARMEN GUILLEN PONCE
@nl
P106
P31
P496
0000-0002-3594-1084